Serotonin research: Contributions to understanding psychoses

Trends in Pharmacological Sciences

Volumn 29, Issue 9, 2008, Pages 445-453

  Geyer, Mark A ^a   Vollenweider, Franz X ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN AGONIST;

ANIMAL; DOSE RESPONSE; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; HUMANS; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; SEROTONIN; SEROTONIN AGONISTS;

EID: 55849099288     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2008.06.006     Document Type: Review

References (60)

1. Stoll, W.A. (1947) Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz. Arch. Neurol. Psychiat 60, 279-323
2. Hasler, F. et al. (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl.) 172, 145-156
3. Hollister, L.E. and Hartmann, A.M. (1962) Mescaline, lysergic acid diethylamid and psilocybin: comparison of clinical syndromes, effects on color perception and biochemical measures. Comparative Psychiatry 3, 235-241
4. Dittrich, A. (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31, 80-84
5. Fischer, R. (1971) A cartography of the ecstatic and meditative states. Science 174, 897-904
6. Hofmann, A. (1968) Psychotomimetic agents. In Chemical Constitution and Pharmacodynamic Actions (2nd edn) (Burger, A., ed.), pp. 169-235, M. Dekker
7. Nichols, D.E. and Chemel, B.R. (2006) The Neuropharmacology of religious experience: hallucinogens and the experience of the divine. In Where God and Science Meet: How Brain and Evolutionary Studies Alter our Understanding of Religion. The Psychology of Religious Experience (Vol. 3) (McNamara, P., ed.), In pp. 1-33, Praeger
8. Bowers, M.B. and Freedman, D.X. (1966) "Psychedelic" experiences in acute psychoses. Arch. Gen. Psychiatry 15, 240-248
9. Chapman, J. (1966) The early symptoms of schizophrenia. Br. J. Psychiatry 112, 225-251
10. Gouzoulis-Mayfrank, E. et al. (1998) History, rationale and potential of human experimental hallucinogen drug research in psychiatry. Pharmacopsychiatry 31, 63-68
11. Gouzoulis-Mayfrank, E. et al. (1998) Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur. Psychiatry 13, 399-406
12. Keeler, M.H. (1965) Similarity of schizophrenia and the psilocybin syndrome as determined by objective methods. Int. J. Neuropsychiatry 1, 630-634
13. Hermle, L. et al. (1998) Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry 31 (Suppl. 2), 85-91
14. Vollenweider, F.X. (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues Clin. Neurosci. 3, 265-279
15. Nichols, D.E. (2004) Hallucinogens. Pharmacol. Ther. 101, 131-181
16. Freedman, B. and Chapman, L.J. (1973) Early subjective experiences in schizophrenic episodes. J. Abnorm. Psychol. 82, 46-54
17. McCabe, M.S. et al. (1972) Symptom differences in schizophrenia with good and poor prognosis. Am. J. Psychiatry 128, 1239-1243
18. Braff, D.L. et al. (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.) 156, 234-258
19. Geyer, M.A. and Braff, D.L. (1987) Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr. Bull. 13, 643-668
20. McGhie, A. and Chapman, J. (1961) Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 34, 103-116
21. Vollenweider, F.X. (1998) Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 31, 92-103
22. Vollenweider, F.X. and Geyer, M.A. (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res. Bull. 56, 495-507
23. Ludewig, K. et al. (2003) Deficits in prepulse inhibition and habituation in never-medicated first-episode schizophrenia. Biol. Psychiatry 54, 121-128
24. Geyer, M.A. and Moghaddam, B. (2002) Animal models relevant to schizophrenia disorders. In Neuropsychopharmacology: The Fifth Generation of Progress (Davis, K.L. et al., eds), pp. 689-701, Lippincott Williams & Wilkins
25. Geyer, M.A. (1998) Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31 (Suppl. 2), 73-79
26. 2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32, 1876-1887
27. Carter, O.L. et al. (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl.) 195, 415-424
28. Vollenweider, F.X. et al. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897-3902
29. 2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl.) 195, 579-590
30. 18F-Setoperone. Am. J. Psychiatry 157, 1016-1018
31. Lieberman, J.A. et al. (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 44, 1099-1117
32. Meltzer, H.Y. (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, 106S-115S
33. Liddle, P.F. et al. (2000) Immediate effects of risperidone on corticostriato-thalamic loops and the hippocampus. Br. J. Psychiatry 177, 402-407
34. Lahti, A.C. et al. (2006) Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology 31, 221-230
35. Sabri, O. et al. (1997) Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 349, 1735-1739
36. Lahti, A.C. et al. (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6, 869-872
37. 2A receptor polymorphisms. Biol. Psychiatry 64, 434-437 (www.sciencedirect.com)
38. Üçok, A. et al. (2007) Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B, 704-707
39. Woolley, D.W. and Shaw, E. (1954) Some neurophysiological aspects of serotonin. BMJ 2, 122-126
40. Shaw, E. and Woolley, D.W. (1956) Some serotoninlike activities of lysergic acid diethylamide. Science 124, 121-122
41. 2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl.) 189, 319-329
42. Aghajanian, G.K. and Marek, G.J. (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21 (Suppl. 2), 16S-23S
43. Geyer, M.A. et al. (1999) The effects of M100907 in pharmacological and developmental animal models of prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology 21, 134-142
44. 2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299, 268-276
45. Geyer, M.A. and Markou, A. (2002) The role of preclinical models in the development of psychotropic drugs. In Neuropsychopharmacology: The Fifth Generation of Progress (Davis, K.L. et al., eds), pp. 445-455, Lippincott Williams & Wilkins
46. Gray, J.A. and Roth, B.L. (2007) The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12, 904-922
47. 2C receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect. 20, 565-571
48. Winters, W.D. (1975) The continuum of CNS excitatory states and hallucinosis. In Hallucinations. Behavior, Experience and Theory (Siegel, R.K. and West, L.J., eds), pp. 53-70, John Wiley and Sons
49. Leuner, H. (ed.) (1981) Halluzinogene: Psychische Grenzzustände in Forschung und Therapie (1st edn), Hans Huber
50. 18F]FDG. Neuropsychopharmacology 20, 565-581
51. Carlsson, A. (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 (Suppl. 1), S10-S14
52. 2A receptors in the ventral pallidum. Brain Res. 761, 97-104
53. Edelman, G.M. (2003) Naturalizing consciousness: a theoretical framework. Proc. Natl. Acad. Sci. U. S. A. 100, 5520-5524
54. 2A receptor-mediated signaling pathways to affect behavior. Neuron 53, 439-452
55. Benneyworth, M.A. et al. (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 72, 477-484
56. González-Maeso, J. et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97
57. Patil, S.T. et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13, 1102-1107
58. Rapport, M.M. et al. (1948) Serum vasoconstrictor, serotonin; chemical inactivation. J. Biol. Chem. 176, 1237-1241
59. Gaddum, J.H. and Hammeed, K.A. (1954) Drugs which antagonize 5-hydroxytryptamine. Br. J. Pharmacol. 9, 240-248
60. Hofmann, A. et al. (1958) [Elucidation of the structure and the synthesis of psilocybin.] (in German). Experientia 14, 397-399